Grew Quarterly Sales 2.5% and Increased Gross Margin 240 Basis Points Retained Jefferies LLC to Assist the Company with Evaluating Strategic Alternatives SALT LAKE CITY, May 07, 2026 (GLOBE NEWSWIRE) — Clarus Corporation (NASDAQ: CLAR) (“Clarus” and/or the “Company”), a global company focused on the outdoor enthusiast markets, reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Financial Summary vs. Same Year‐Ago QuarterSales of $61.9 million compared to $60.4 million. Gross margin was 36.8% compared to 34.4%; adjusted gross margin of 36.8% compared to 34.6%. Net loss of $3.3 million with a net loss margin of (5.3)%, or $(0.09) per diluted share, compared to net loss of $5.2 million with a net loss margin of (8.7)%, or $(0.14) per diluted share. Adjusted net income of $0.7 million, or $0.02...

Meeting with FDA Division of Psychiatry scheduled for May 2026 expected to informregistrational plans for zervimesine in DLB psychosis PURCHASE, N.Y., May 07, 2026 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc. (NASDAQ: CGTX), clinical-stage company developing product candidates that treat neurodegenerative disorders, (the “Company” or “Cognition”), today reported financial results for the first quarter ended March 31, 2026, and provided a business update. “We filed a request to meet with the Food and Drug Administration’s Division of Psychiatry to discuss our plans for a registrational study in people with dementia with Lewy body (DLB) psychosis,” stated Lisa Ricciardi, Cognition’s president and CEO. “We recently received our meeting invitation for May 20, 2026 and we are looking forward to a productive conversation so we can...

Net Premiums Earned Growth of 28% for Q1 2026 | Direct Premiums Written Growth1 of 20% for Q1 2026 Q1 GAAP Net Combined Ratio of 112.0% Driven by Eleven Winter Catastrophe Events in the Northeast U.S.Q1 Underlying Combined Ratio1 Improved 5.1 Points to 88.3%Q1 Diluted Net Loss Per Share of $0.40 | Q1 Diluted Operating Net Loss Per Share1 of $0.35 Company Reaffirms 2026 Full Year Guidance Management to Host Conference Call Tomorrow at 8:30 a.m. Eastern Time KINGSTON, N.Y., May 07, 2026 (GLOBE NEWSWIRE) — Kingstone Companies, Inc. (Nasdaq: KINS) (“Kingstone” or the “Company”), a regional property and casualty insurance holding company, today announced its financial results for the first quarter ended March 31, 2026. The Company has also provided an investor presentation that can be accessed through the News & Events/Presentations...

AUDUBON, Pa., May 07, 2026 (GLOBE NEWSWIRE) — Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced its financial results for the first quarter ended March 31, 2026. First Quarter 2026:Worldwide net sales were $759.9 million, an increase of 27.0%, or an increase of 25.5% on a constant currency basis. Base business, excluding Nevro, net sales were $677.2 million, an increase of 13.2%, or an increase of 11.2% on a constant currency basis. GAAP net income for the quarter was $124.3 million. GAAP diluted earnings per share (“EPS”) was $0.90, an increase of 66.6%. Non-GAAP diluted EPS was $1.12, an increase of 64.7%.“We’re off to a strong start in 2026 with 27% overall revenue growth and record first quarter earnings. Organic revenue grew over 13%, driven by share gains and procedural volume...

First Quarter Financial Highlights:Total revenues decreased $12.5 million year over year to $410.5 million. On an organic basis*, revenues decreased $8.6 million year over year, or 2.1% Material Handling revenues decreased $7.4 million year over year to $150.5 million, while Construction Equipment and Master Distribution revenues decreased a combined $1.8 million year over year to $261.4 million. On an organic basis*, Material Handling and Construction Equipment segment revenues were down $4.7 million and $0.3 million year over year, respectively Material Handling and Construction Equipment segments new and used equipment sales gross profit margins both remained stable year over year at 19.6% and 11.7%, respectively, and improved notably on a sequential basis Service gross profit percentage increased 10 basis points year over year to...

PRESS RELEASE                NON-REGULATED INFORMATIONLuxembourg, May 7, 2026, 5:55 PM                                                                                                                                           Nextensa and Promobe sell B&B HOTELS at Cloche d’OrLuxembourg, May 7, 2026 – Promobe and Nextensa announce to have sold their shares in Sparkling 1 S.à r.l., the company that owns the B&B HOTELS at Cloche d’Or district, for a value of €37.4 M. The purchaser is Aberdeen Investments, acting on behalf of Irish Life Investment Managers. Opened in September 2025, this B&B HOTELS marked the French hotel brand’s debut in Luxembourg. The joint venture between Promobe and Nextensa, and the project’s developer, Grossfeld oversaw the development and delivery of the building in July 2025. The hotel,...

Date: 7 May 2026 Release: After closing of Euronext Please open the following link to read the full report including annexes:AttachmentFULL PRESS RELEASE

The Interim Financial Statements of Eik fasteignafélag hf. for the period from 1 January to 31 March 2026 were approved by the Board of Directors and the CEO on 7 May 2026. Enclosed is the interim report, which includes the Interim Financial Statements for the first three months of the year along with detailed information about the Company’s operations as presented in the announcement. The key results of the Interim Financial Statements areIncome from operations amounted to ISK 3,509 millionThereof, rental income amounted to ISK 3,094 millionOperating profit before changes in fair value and depreciation amounted to 2,206 million Total comprehensive profit amounted to ISK 977 million. Net cash from operations amounted to ISK 1,474 million. The book value of investment properties amounted to ISK 175,182 million.  Change in fair...

        PRESS RELEASE                 Paris, 7th May 2026 Unaudited interim results at end March 2026 Solid fundamentals driving revenue growth, with strengthened efficiency gains lifting operational profitabilityPublic funding to mitigate cost inflation still a challenge9M Group Revenue up 3.1% to €4.0bn (+1.9% LFL) from (i) a recognized quality offering driving volumes in France and (ii) strong fundamentals in the Nordics, with positive price indexation, favourable currency effects, and the first quarter of contribution from the new St Göran contract. 9M Group EBITDA up 4.4% at €460m (11.6% margin), with efficiency, performance improvement and sustained operating cost control offsetting (i) the anticipated €20m shortfall in French revenue guarantee, (ii) the impact of a strike by French medical practitioners in January 2026 protesting...

May 7, 2026 Copenhagen, Denmark; Interim Report for the Three Months Ended March 31, 2026 HighlightsGenmab revenue increased 25% compared to the first three months of 2025, to $896 million FDA approved an sBLA to remove the recommendation for 24-hour hospitalization for patients with third line plus relapsed/refractory DLBCL Remained focused on disciplined investment in our late-stage portfolio, EPKINLY® (epcoritamab), Rina-S®, and petosemtamab, including launch readiness“We made tangible progress in the first quarter as we continue to integrate Merus™ and advance our late-stage portfolio – EPKINLY, Rina-S and petosemtamab. Across the business, our focus remained on disciplined execution, progressing these programs toward key readouts and preparing for potential launches to have an impact on more patients,” said Jan...